AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01364142 — intervention group
Intervention type: PROCEDURE
Intervention: endobronchial blocker
Description: After intubation of endotracheal tube, the Uniblocker® was inserted into the endotracheal tube and advanced step by step with inflation of the blocker balloon until the peak inspiratory pressure dropped abruptly.
Study NCT00529412 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Seprafilm
Description: two sheets per body
Study NCT00529412 — intervention group
Intervention type: OTHER
Group type: NO_INTERVENTION
Intervention: Seprafilm
Description: two sheets per body
Study NCT00072046 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: 10mg/kg IV infusion on Days 1 \& 15 of each cycle
Study NCT00072046 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: recombinant interferon alfa
Description: 9 million units subQ injection 3 x/week for 4 weeks
Study NCT00802724 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Classification-directed treatment
Description: People in the Classification-directed treatment will be treated based on their direction-specific LBP classification. Treatment will consist of 3 primary components. The first component of treatment will be analysis and instruction in modification of the person's direction-specific alignment and movement strategies during symptomatic functional activities and activities in which the person uses similar strategies to those displayed with symptomatic functional activities. The second component is education about the principles of tissue injury and healing and the need to keep active. The third component is exercise prescription that consists of practice in performance of modified versions of the direction-specific impairment tests from the exam, with an emphasis on impairments that can be modified to eliminate symptoms.
Study NCT00802724 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Non-specific treatment
Description: People in the Non-specific treatment will be provided treatment that incorporates treatment commonly cited in the literature for people with chronic LBP. The first component of treatment will consist of training in functional activities based on biomechanical principles. The second component will include general education about low back pain. The third component is exercise prescription that is directed at improving the strength and flexibility of the trunk and limbs.
Study NCT05848336 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Gluten Free Casein Free Diet
Description: Thirty children with autism were evaluated before the diet (Pre-Test) and after 8 weeks of dietary intervention (Post-Test).
Study NCT02950441 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Nicotinamide Riboside
Study NCT02950441 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT00650897 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Escitalopram
Description: 10-20 mg once daily
Study NCT02561104 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laser-assisted cataract surgery.
Study NCT02561104 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Traditional manual phacoemulsification
Study NCT04629586 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: Observational research study
Study NCT01605890 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: emtricitabine / tenofovir disoproxil fumarate / raltegravir .
Description: emtricitabine : 200 mg/day and tenofovir disoproxil fumarate : 300 mg/day, included in one pill of Truvada® QD.~raltegravir : 400 mg x 2/day, 400 mg in one pill of Isentress® BID.
Study NCT00130494 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zoledronic acid
Study NCT00598806 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apaziquone
Description: A single intravesical dose of Apaziquone 4mg in 40ml instilled into the bladder post-TURBT
Study NCT02190708 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: single oral dose on day1 and day 6
Study NCT02190708 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omeprazole
Description: single oral dose on day1 and day6
Study NCT03486600 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Fluid Resuscitation
Description: Patients will be evaluated and the bleeding site to be investigated and hemorrhagic shock confirmed and there is an expected delay in blood and blood products transfusion for more than 40 minutes. 6% HES 130/0.4 (Voluven®) will be administered intravenously to maintain or restore hemodynamic stability up to a maximum dose of 50 mL/kg body weight.
Study NCT00163046 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gabapentin
Description: Gabapentin 250 mg oral capsule 30 minutes prior to bedtime for 28 days
Study NCT00598806 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A single intravesical dose of placebo instilled into the bladder post-TURBT
Study NCT00598806 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TURBT
Description: TransUrethral Resection of the Bladder Tumor
Study NCT00598806 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: TURBT
Description: TransUrethral Resection of the Bladder Tumor
Study NCT03345173 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CI-581-a
Description: Two infusions in the context of naltrexone induction protocol.
Study NCT03345173 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: CI-581-b
Description: Two infusions in the context of naltrexone induction protocol.
Study NCT02314286 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Description: Rosuvastatin is a hydrophilic statin, short treatment (hours to days) with this type of statin improved the outcome of patients during acute myocardial infarction, sepsis, contrast-induced nephropathy, hepatic ischemia/reperfusion injury, emphasizing its preferential pleiotropic effects. Currently, the FDA classiﬁes all statins as pregnancy category X and discourages their use during pregnancy due to higher abortion rate and teratogenicity that were observed in animals exposed to hydrophobic statins during pregnancy. Since the use of statins after delivery is allowed, the present study will aim to evaluate whether Rosuvastatin may accelerates preeclampsia resolution following delivery and potentially reduce postpartum preeclampsia complications.
Study NCT02314286 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02277236 — intervention group
Intervention type: RADIATION
Intervention: DXA scanning
Description: Exposure: Participants will undergo DXA scanning in the supine position per manufacturer guidelines to estimate absolute and percentage of total lean body mass (LBM) and body fat (BF).
Study NCT00574041 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interferon beta-1a
Description: injected, once a week
Study NCT02277236 — intervention group
Intervention type: RADIATION
Intervention: CT imaging
Description: Exposure: Estimates of intramuscular adipose tissue (IMAT) will be obtained with CT imaging. This measure will be restricted to a single leg (dominant side) in the mid-femur region, using a single 10mm axial image slice (120 kVp, 200 to 250 mA).
Study NCT00938197 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fimasartan
Description: Fimasartan (1d\~7d) Amlodipine (12d\~14d) Fimasartan + Amlodipine(15d\~21d)
Study NCT00938197 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amlodipine
Description: Amlodipine (1d\~10d) Amlodipine (25d\~27d) Fimasartan + Amlodipine(28d\~34d)
Study NCT05243147 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: nasal stents
Description: using nasal stents after septoplasty
Study NCT05243147 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: merocel
Description: using merocel after septoplasty
Study NCT01966276 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methyl-P plus Nutrient Formula
Description: * Week 1 (take the following together twice a day-at breakfast and lunch)~  * One tablet of Methyl-P (5mg)~ * Four tablets of CFS Nutrient Formula~* Week 2 to Week 12 (take the following together twice a day-at breakfast and lunch):~  * Two tablets of Methyl-P (10mg)~ * Four tablets of CFS Nutrient Formula
Study NCT01966276 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Methyl-P plus Nutrient matched placebos
Description: * Week 1 (take the following together twice a day-at breakfast and lunch)~  * One tablet of Methyl-P Placebo~ * Four tablets of CFS Nutrient Placebo~* Week 2 to Week 12 (take the following together twice a day-at breakfast and lunch):~  * Two tablets of Methyl-P Placebo~ * Four tablets of CFS Nutrient Placebo
Study NCT04724772 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic acid injection
Description: Injection of tranexamic acid preoperatively
Study NCT02415504 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Enhanced care transition
Description: Enhanced care transition discharge package: (1) an integrated behavioural care plan, (2) an in-person discharge meeting including family, post-care transition staff (LTC or another hospital unit) and unit staff, (3) videos of responsive behaviours and non-pharmacological interventions, (4) a briefcase of favoured activities, (5) an in-person care demonstration, and (6) involvement of a transitional care team.
Study NCT02415504 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Standard care transition
Description: Standard care transition discharge package: The standard care transition varies by unit, and either consists of: (1) a discipline specific care plan, (2) a phone discharge meeting between unit staff and post-care transition staff (LTC or another hospital unit) and (3) a follow-up phone call with social work OR (1) a discipline specific care plan, (2) an in-person meeting between unit staff and (family) caregivers, (3) involvement of a transitional care team, and (4) a follow-up phone call with social work.
Study NCT05001581 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Arthroscopic partial repair of massive rotator cuff tear
Description: Surgery relies on arthroscopic reconstruction of the rotator cuff tendons. Because of irreparability of Supraspinatus tendon ( always) and infraspinatus tendon ( sometimes) surgeon performed partial repair to cover humeral head by the tendons
Study NCT05001581 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Arthroscopic partial repair of rotator cuff with biceps augmentation
Description: Surgery relies on arthroscopic reconstruction of the rotator cuff tendons. Because of irreparability of Supraspinatus tendon ( always) and infraspinatus tendon ( sometimes) surgeon performed partial repair to cover humeral head by the tendons and because of good quality of the long head of the biceps tendon, its uses as biological reinforcement of the reconstruction to achieve better clinical and radiological outcome
Study NCT00574041 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Interferon beta-1a
Description: injected, once a week
Study NCT00163046 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matched placebo 30 minutes prior to bedtime for 28 days
Study NCT03886194 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: interventional treatment in pulmonary
Description: Thrombolytic group: urokinase 20,000 units / kg body weight, 2 hours intravenous drip; or rtPA 50mg, 2 hours intravenous drip; and interventional treatment group: intracavitary catheter contact thrombolysis (urokinase 500,000 u 5 minute pulse Give), catheter thromboembolism, thrombus aspiration and mechanical thrombectomy.
Study NCT03886194 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: interventional treatment in pulmonary
Description: Thrombolytic group: urokinase 20,000 units / kg body weight, 2 hours intravenous drip; or rtPA 50mg, 2 hours intravenous drip; and interventional treatment group: intracavitary catheter contact thrombolysis (urokinase 500,000 u 5 minute pulse Give), catheter thromboembolism, thrombus aspiration and mechanical thrombectomy.
Study NCT00988052 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Laquinimod
Description: One capsule containing 0.6 mg laquinimod to be administered orally once daily.
Study NCT02223052 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-486
Description: Arm 1: Two 150-mg tablets of CC-486 on Day 1 and 1 x 300 mg CC-486 on Day 2 Arm 2: 1 x 300mg tablet of CC 486 on Day 1 and 2 x 150mg CC-486 on Day 2
Study NCT00056966 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ANTI-CD45
Description: 400ug/kg Day-5 through Day-2
Study NCT02223052 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vidaza
Description: 75mg/m\^2 IV or SC daily x 7 days every 4 weeks for ≤ 6 (four-week) cycles
Study NCT03202498 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: 4g Placebo
Description: Study patients will be dosed daily with a quantity of placebo equivalent to 4g of product Yaq-001 for a period of 12 weeks. The product will be provided as beads packed in individual sachets intended each for one oral administration. For each patient, the study duration will be up to 17 weeks, including the screening (up to 4 weeks), treatment (12 weeks) and 7-day follow up period.
Study NCT03202498 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 8g Yaq-001
Description: Study patients will be dosed daily with 8g of product Yaq-001 for a period of 12 weeks. The product will be provided as beads packed in individual sachets intended each for one oral administration. For each patient, the study duration will be up to 17 weeks, including the screening (up to 4 weeks), treatment (12 weeks) and 7-day follow up period.
Study NCT03202498 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: 8g Placebo
Description: Study patients will be dosed daily with a quantity of placebo equivalent to 8g of product Yaq-001 for a period of 12 weeks. The product will be provided as beads packed in individual sachets intended each for one oral administration. For each patient, the study duration will be up to 17 weeks, including the screening (up to 4 weeks), treatment (12 weeks) and 7-day follow up period.
Study NCT00542854 — intervention group
Intervention type: DEVICE
Intervention: MP3
Description: 4 different brands of MP3 players will be tested at 3 distances from ICD/pacemaker site in children and adults with congenital heart disease.
Study NCT02471430 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Panobinostat
Description: Panobinostat will be administered orally.
Study NCT02471430 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegylated Interferon-alpha2a
Description: Pegylated Interferon-alpha2a will be administered subcutaneously in one shot.
Study NCT04489680 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational
Description: Teaching session
Study NCT02716454 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ileocaecal resection
Description: laparoscopic ileocaecal resection with primary anastomosis
Study NCT04173468 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Moblization with Movement
Description: patients with group 1 will receive two techniques pertaining to MWM intervention (straight leg raised with traction and tibial Gliding) Repeat it 10 times,3 sets and 1 mint interval. .For Tibial Gliding we will asks the patient to perform 10 repetitive active knee extensions. Practice will be performed by doing 10 reps for 3 sets with 1 min interval. After this home exercises will b guided stretching of hamstrings 8 to 10 reps 20 sec hold, strengthening of Quadriceps and VMO with 10 reps and 3 sets
Study NCT04173468 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Mulligan knee taping
Description: patient with group 2 will receive Mulligan taping technique. Tape will be applied for two days then we will change it. After this home based exercise will be guided which is stretching of hamstrings 8 to 10 reps 20 sec hold , strengthening of Quadriceps and VMO with 10 reps and 3 sets.
Study NCT01581814 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: 500 mg of Metformin per 3/die
Study NCT01581814 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Yasmin;
Description: 1pill/day for cycles of 28 days (21 pills followed by 7 no-pill days)
Study NCT01581814 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin plus Yasmin
Description: 0.03 mg EE plus 3 mg of DRPS combined with 500 mg of metformin three times daily
Study NCT01761890 — intervention group
Intervention type: BEHAVIORAL
Intervention: Dasatinib discontinuation
Description: Treatment decision is at the discretion of the investigator and must not be made on the basis of this observational study. Patients should have their treatment initiated in accordance with the summary of product characteristics.
Study NCT04083053 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Perianal Exam
Description: Perianal Exam is part of anal cancer screening. The perianal skin is also examined under magnification and, less commonly, perianal biopsies are obtained.
Study NCT00849355 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RCOMP-14 + rituximab
Description: Pretreatment: vincristine 1mg at day -6 and Methylprednisolone 100 mg from -6 to day 0.~Treatment: rituximab 375m/m2 + ciclophosphamide 750 mg/m2 + Vincristine 1.4 mg/m2 + Doxorrubicine 50 mg/m2 at day 1 and every 14d. Prednisone 100 mg/d from day 1 to 5 and every 14 d.
Study NCT00681395 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-143
Description: once daily for 6 days
Study NCT04083053 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: high-resolution anoscopy (HRA) with biopsy
Description: The HRA exam involves insertion of a plastic anoscope 4-6 cm into the anal canal, with use of 5% acetic acid and Lugol's iodine to highlight abnormal lesions for biopsy. The entire squamocolumnar junction is visualized during the exam, which lasts between 5 and 20 minutes.
Study NCT03120416 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Resistance exercise training
Description: 12-week resistance exercise training program, 2 times per week, 45 min per session. Eight exercises will be used to include large upper and lower body muscle groups (leg press, leg extension, leg curl, chest press, shoulder extension, biceps curl, abdominal crunch and back extension). The baseline one repetition maximum will be used to set initial training loads.
Study NCT02155608 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active eTNS
Description: Participants will receive active trigeminal nerve stimulation (TNS) administered by the Monarch eTNS System nightly during sleep for 4 weeks, followed by one week of observation and followup while remaining blinded following treatment discontinuation. Participant deemed to be positive responders to blinded active treatment will be invited to continue open eTNS in a 12 month extension period.
Study NCT02155608 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham eTNS
Description: Participants will receive sham trigeminal nerve stimulation (TNS) administered by the Monarch eTNS System nightly during sleep for 4 weeks, followed by one week of observation and followup while remaining blinded following treatment discontinuation. At the conclusion of the blinded trial, participants randomized to the sham group will be offered 4 weeks of open eTNS treatment. Participants deemed to be positive responders to open treatment will be invited to continue open nightly eTNS in a 12 month extension period.
Study NCT00005640 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Preoperative Endoscopy
Study NCT00005640 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Technetium Tc 99m Sulfur Colloid
Study NCT00005640 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Gamma Probe
Study NCT00005640 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy of Sentinel Lymph Nodes
Study NCT02454894 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lidocaine
Description: surface anesthesia with lidocaine
Study NCT02454894 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: postoperative management
Description: lying without the pillow for half an hour after lumbar puncture
Study NCT01045876 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: One dose of 8 mg of Dexamethasone intravenously at induction of anesthesia
Study NCT01045876 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2 ml of 0.9% Saline Solution administered intravenously at induction of anesthesia
Study NCT02433691 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: simultaneous aerobic exercise
Description: stationary bicycling at 65% of heart rate reserve for 30 minutes while receiving memory training.
Study NCT02433691 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: sequential aerobic exercise
Description: stationary bicycling at 65% of heart rate reserve for 30 minutes followed by memory training.
Study NCT02433691 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: stretching and toning
Description: anaerobic stretching and toning followed by memory training.
Study NCT03325010 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valbenazine
Description: vesicular monoamine transporter 2 (VMAT2) inhibitor
Study NCT03495362 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Yeast Beta-glucan
Description: Twice a day, 1 capsule each time. Do not take any other medicine, traditional Chinese medicine, or dietary supplements.